エクソソームの世界市場 - 市場規模、シェア、成長分析：用途別、製品タイプ別、エンドユーザー別、ワークフロー別、生体分子タイプ別 - 業界予測（2022年～2028年）

世界のエクソソームの市場規模は、2022年の1,122億5,000万米ドルから2030年までに8兆7,939億5,000万米ドルに達し、予測期間（2023年～2030年）にCAGRで32.75%の成長が予測されています。研究活動の活発化、技術の進歩、バイオテクノロジー企業や製薬企業による投資の増加により、市場の拡大が見込まれています。

当レポートでは、世界のエクソソーム市場について調査分析し、市場力学と見通し、セグメント分析、企業プロファイルなどを提供しています。

目次

エグゼクティブサマリー

調査手法

親市場の分析

主な市場の考察

• 技術分析
• 価格分析
• サプライチェーン分析
• バリューチェーン分析
• 市場のエコシステム
• IP分析
• 貿易分析
• スタートアップ分析
• 原材料の分析
• イノベーションマトリックス
• パイプライン製品の分析
• マクロ経済指標
• 主な投資の分析
• 主な成功要因
• 競合の程度

市場力学と見通し

• 市場力学
• 促進要因
• 機会
• 抑制要因
• 課題
• 規制情勢
• ポーターのファイブフォース分析
• 将来の混乱についての特別な考察

世界のエクソソーム市場：用途別

• 市場の概要
• 診断
• 治療用途

世界のエクソソーム市場：製品別

• 市場の概要
• 器具
• 試薬
• ソフトウェア

世界のエクソソーム市場：エンドユーザー別

• 市場の概要
• がん研究所
• 病院
• 診断センター
• その他（医科大学、非営利組織）

世界のエクソソーム市場：ワークフロー別

• 市場の概要
• 隔離
• 下流分析

世界のエクソソーム市場：生体分子タイプ別

• 市場の概要
• ノンコーディングRNA
• mRNA
• タンパク質
• 脂質

世界のエクソソームの市場規模：地域別

• 市場の概要
• 北米
• 米国
• カナダ
• 欧州
• ドイツ
• スペイン
• フランス
• 英国
• その他の欧州
• アジア太平洋
• 中国
• インド
• 日本
• 韓国
• その他のアジア太平洋
• ラテンアメリカ
• ブラジル
• その他のラテンアメリカ
• 中東・アフリカ
• GCC諸国
• 南アフリカ
• その他の中東・アフリカ

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2021年）
• 主要市場企業が採用した戦略
• 主な成功戦略
• 市場における最近の活動
• 主要企業の市場シェア（2021年）

主要企業プロファイル

• Danaher (Beckman Coulter Inc.) (US)
• Diagenode Inc. (US)
• Fujifilm Holdings Corporation (Japan)
• Hitachi Chemical Diagnostics Inc. (US)
• Lonza (Switzerland)
• MBL International (US)
• Miltenyi Biotec (Germany)
• Novus Biologicals (US)
• Qiagen (Germany)
• Thermo Fisher Scientific Inc. (US)

Exosomes Market size was valued at USD 84.49 billion in 2021 and is poised to grow from USD 112.25 billion in 2022 to USD 8793.95 billion by 2030, growing at a CAGR of 32.75% in the forecast period (2023-2030).

The global exosomes market refers to the commercial activities related to the isolation, purification, and characterization of exosomes, which are extracellular vesicles secreted by most cell types. Exosomes play important roles in intercellular communication, and their diagnostic and therapeutic potential is being explored in various fields, including cancer, regenerative medicine, and drug delivery. The market is expected to grow due to increasing research activities, technological advancements, and rising investments by biotechnology and pharmaceutical companies. However, challenges such as standardization, scalability, and regulatory issues need to be addressed for the successful translation of exosome-based products into clinical practice.

Top-down and bottom-up approaches were used to estimate and validate the size of Exosomes market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report

The Global Exosomes Market is segmented based on the Application, Product, End-User, and region. Based on the Application, the Market is segmented into diagnostic and therapeutic applications. Based on the Product, the Market is segmented into instruments, reagents, and software. Based on the End-User, the Market is segmented as cancer institute, hospitals, diagnostic centers, and others (medical universities and not-for-profit organizations). Based on Region it is categorized into North America, Europe, Asia-Pacific, Latin America, and MEA.

Driver

The development of novel drugs and medical devices involves substantial investments from pharmaceutical, biopharmaceutical, and medical device companies. These businesses allocate significant resources to research and development (R&D) in order to offer innovative and top-quality products to the market. As per current patterns, major players in the pharmaceutical industry are boosting their R&D efficiency by making substantial and enduring investments in R&D, as well as by collaborating on joint R&D ventures. This strategy helps these companies to remain at the forefront of the industry and continue to bring new and improved products to consumers.

Restrain

The field of exosome research is still in its early stages, lacking established standards. As a result, professionals readily adopt new techniques and processes available on the market. In addition to the challenges of exosome creation, scientists face obstacles in their research, development, and manufacturing. Recently, exosomes derived from MSCs have garnered attention due to their function as intercellular messengers. These unique properties make them attractive for scientific applications such as cancer diagnostics, vaccine development, gene therapy, cell treatment, and drug administration. Therefore, to successfully harvest exosomes and establish industry-leading standards for their purification and characterization, developers of MSC-exosome treatments must adapt their stem cell-free therapy process to meet the demands of exosome manufacturing.

Trend

Exosomes have emerged as a promising treatment approach for various ailments, including COVID-19. These tiny vesicles have been utilized in the medical field to transport therapeutic payloads, circumventing issues like immune rejection and cellular harm. As a cell-free alternative, they offer a potential solution for treating diverse diseases and promoting tissue repair. Specifically, exosomal therapy targeted towards respiratory viral infections, such as SARS-CoV-2, can be developed using stem cell-derived exosomes, which possess favorable anti-inflammatory and regenerative traits inherited from their parent cells.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune
• Research Methodology
• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
• Drivers
• Opportunities
• Restraints
• Challenges
• Key Market Insights
• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition
• Market Dynamics & Outlook
• Market Dynamics
• Drivers
• Opportunities
• Restraints
• Challenges
• Regulatory Landscape
• Porters Analysis
• Competitive rivalry
• Threat of Substitute Products
• Bargaining Power of Buyers
• Threat of New Entrants
• Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
• Political Impact
• Economic Impact
• Social Impact
• Technical Impact
• Environmental Impact
• Legal Impact

Global Exosomes Market by Application

• Market Overview
• Diagnostic
• therapeutic applications
• Global Exosomes Market by Product
• Market Overview
• Instruments
• reagents
• software
• Global Exosomes Market by End-User
• Market Overview
• Cancer institute
• hospitals
• diagnostic centers
• others (medical universities
• not-for-profit organizations)
• Global Exosomes Market by Workflow
• Market Overview
• Isolation
• Downstream Analysis
• Global Exosomes Market by Biomolecule Type
• Market Overview
• Non-coding RNA
• mRNA
• Protein
• Lipid
• Global Exosomes Market Size by Region
• Market Overview
• North America
• USA
• Canada
• Europe
• Germany
• Spain
• France
• UK
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC Countries
• South Africa
• Rest of MEA
• Competitive Landscape
• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
• By Development
• By Company
• By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021
• Key Company Profiles
• Danaher (Beckman Coulter Inc.) (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
• Diagenode Inc. (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
• Fujifilm Holdings Corporation (Japan)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
• Hitachi Chemical Diagnostics Inc. (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
• Lonza (Switzerland)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
• MBL International (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
• Miltenyi Biotec (Germany)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
• Novus Biologicals (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
• Qiagen (Germany)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
• Thermo Fisher Scientific Inc. (US)
• Company Overview
• Business Segment Overview
• Financial Updates